Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes

Kidney International

Volumn 79, Issue 10, 2011, Pages 1090-1098

  Awad, Alaa S ^a,b,c   Rouse, Michael D ^a   Khutsishvili, Konstantine ^a,b   Huang, Liping ^a,b   Bolton, W Kline ^a,b   Lynch, Kevin R ^a   Okusa, Mark D ^a,b,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

diabetic nephropathy; inflammation; lymphocytes; podocyte

Indexed keywords

5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; FINGOLIMOD; MESSENGER RNA; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DRUG EFFICACY; KIDNEY FUNCTION; LYMPHOCYTE COUNT; MACROPHAGE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79955596917     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.544     Document Type: Article

References (43)

1. Parving HH, Osterby R, Ritz E. Diabetic nephropathy. In: Brenner BM (ed). The Kidney. WB Saunders Company: Philadelphia, 2000 pp 1731-1773.
2. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219. (Pubitemid 28327814)
3. Nikolic-Paterson DJ, Atkins RC. The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 2001; 16(Suppl 5): 3-7. (Pubitemid 32750422)
4. Bending JJ, Lobo-Yeo A, Vergani D et al. Proteinuria and activated Tlymphocytes in diabetic nephropathy. Diabetes 1988; 37: 507-511.
5. Moriya R, Manivel JC, Mauer M. Juxtaglomerular apparatus T-cell infiltration affects glomerular structure in Type 1 diabetic patients. Diabetologia 2004; 47: 82-88. (Pubitemid 38141943)
6. Mensah-Brown EP, Obineche EN, Galadari S et al. Streptozotocin-induced diabetic nephropathy in rats: the role of inflammatory cytokines. Cytokine 2005; 31: 180-190. (Pubitemid 40967901)
7. Hla T, Lee MJ, Ancellin N et al. Lysophospholipids-receptor revelations. Science 2001; 294: 1875-1878.
8. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005; 5: 560-570. (Pubitemid 40961333)
9. Awad AS, Ye H, Huang L et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 2006; 290: F1516-F1524. (Pubitemid 43830779)
10. Lien YH, Yong KC, Cho C et al. S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int 2006; 69: 1601-1608.
11. Mandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349. (Pubitemid 34303689)
12. Pinschewer DD, Ochsenbein AF, Odermatt B et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000; 164: 5761-5770. (Pubitemid 30389819)
13. Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-21457. (Pubitemid 34952287)
14. Fujino M, Funeshima N, Kitazawa Y et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 70-77. (Pubitemid 36378136)
15. Kitabayashi H, Isobe M, Watanabe N et al. FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J Cardiovasc Pharmacol 2000; 35: 410-416. (Pubitemid 30127188)
16. Kurose S, Ikeda E, Tokiwa M et al. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp Eye Res 2000; 70: 7-15. (Pubitemid 30046870)
17. Okazaki H, Hirata D, Kamimura T et al. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 2002; 29: 707-716. (Pubitemid 34303864)
18. Keul P, Tolle M, Lucke S et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 607-613.
19. Maki T, Gottschalk R, Monaco AP. Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantation 2002; 74: 1684-1686. (Pubitemid 36019318)
20. Maki T, Gottschalk R, Ogawa N et al. Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation 2005; 79: 1051-1055. (Pubitemid 40663996)
21. Yang Z, Chen M, Fialkow LB et al. The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice small star, filled. Clin Immunol 2003; 107: 30-35. (Pubitemid 36539443)
22. Kappos L, Radue EW, O'Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
23. Bajwa A, Jo SK, Ye H et al. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol 2010; 21: 955-965.
24. Chiba K, Yanagawa Y, Masubuchi Y et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998; 160: 5037-5044. (Pubitemid 28215340)
25. Jo SK, Bajwa A, Ye H et al. Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int 2009; 75: 167-175.
26. Kluk MJ, Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDGfamily of G-protein-coupled receptors. Biochim Biophys Acta 2002; 1582: 72-80. (Pubitemid 34634113)
27. Lee MJ, Thangada S, Claffey KP et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1- phosphate. Cell 1999; 99: 301-312. (Pubitemid 29519909)
28. Krump-Konvalinkova V, Yasuda S, Rubic T et al. Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells. Arterioscler Thromb Vasc Biol 2005; 25: 546-552. (Pubitemid 40315676)
29. Goetzl EJ, Rosen H. Regulation of immunity by lysosphingolipids and their G protein-coupled receptors. J Clin Invest 2004; 114: 1531-1537. (Pubitemid 40385541)
30. Awad AS, Huang L, Ye H et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F828-F837. (Pubitemid 43724943)
31. Baud L, Oudinet JP, Bens M et al. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 1989; 35: 1111-1118. (Pubitemid 19167896)
32. Hruby ZW, Lowry RP. Spontaneous release of tumor necrosis factor alpha by isolated renal glomeruli and cultured glomerular mesangial cells. Clin Immunol Immunopathol 1991; 59: 156-164.
33. Royall JA, Berkow RL, Beckman JS et al. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am J Physiol 1989; 257: L399-L410.
34. Nakamura T, Fukui M, Ebihara I et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993; 42: 450-456. (Pubitemid 23066522)
35. Ishii M, Egen JG, Klauschen F et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009; 458: 524-528.
36. Yanagawa Y, Sugahara K, Kataoka H et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998; 160: 5493-5499. (Pubitemid 28267841)
37. Morales-Ruiz M, Lee MJ, Zollner S et al. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a G protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem 2001; 276: 19672-19677.
38. Gon Y, Wood MR, Kiosses WB et al. S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. Proc Natl Acad Sci USA 2005; 102: 9270-9275. (Pubitemid 40923553)
39. Dedhar S, Jewell K, Rojiani M et al. The receptor for the basement membrane glycoprotein entactin is the integrin alpha 3/beta 1. J Biol Chem 1992; 267: 18908-18914.
40. Schwarz K, Simons M, Reiser J et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108: 1621-1629. (Pubitemid 33144872)
41. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999; 42: 1341-1344. (Pubitemid 29500971)
42. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348. (Pubitemid 27053474)
43. Awad AS, Rouse M, Liu L et al. Activation of adenosine 2A receptors preserves structure and function of podocytes. J Am Soc Nephrol 2008; 19: 59-68.